Identification of two molecular groups of seminomas by using expression and tissue microarrays

Clinical Cancer Research

Volumn 11, Issue 16, 2005, Pages 5722-5729

  Hofer, Matthias D ^a,b   Browne, Tara J ^a,b   He, Le ^a   Skotheim, Rolf I ^c   Lothe, Ragnhild A ^c   Rubin, Mark A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE PLACENTA ISOENZYME; ANTIBODY; CARRIER PROTEIN; CD30 ANTIGEN; CYTOKERATIN; CYTOKERATIN CLONE 5.2 ANTIBODY; CYTOKERATIN EXCHANGER 1; CYTOKERATIN EXCHANGER 3; JUNCTION PLAKOGLOBULIN; M PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CDC6 GENE; EMBRYONAL CARCINOMA; EXPRESSION ARRAY ANALYSIS; GENE EXPRESSION; GENE OVEREXPRESSION; GERM CELL TUMOR; GRB7 GENE; HUMAN; HUMAN TISSUE; IGF2 GENE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; JUP GENE; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; NET 7 GENE; NONSEMINOMATOUS GERM CELL TUMOR; PFKP GENE; POU DOMAIN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SEMINOMA; SEMINOMATOUS GERM CELL TUMOR; SLC43A1 GENE; TISSUE MICROARRAY;

AMINO ACID TRANSPORT SYSTEM Y+L; CELL CYCLE PROTEINS; CLUSTER ANALYSIS; DESMOPLAKINS; GAMMA CATENIN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GRB7 ADAPTOR PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEINS; SEMINOMA; TESTICULAR NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 23844444155     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0533     Document Type: Article

References (26)

1. Bergstrom R, Adami HO, Mohner M, et al. Increase in testicular cancer incidence in six European countries: a birth cohort phenomenon. J Natl Cancer Inst 1996;88:727-33.
2. Devesa SS, Blot WJ, Stone BJ, Miller BA, Tarone RE, Fraumeni JF, Jr. Recent cancer trends in the United States. J Natl Cancer Inst 1995;87:175-82.
3. Dieckmann KP, Skakkebaek NE. Carcinoma in situ of the testis: review of biological and clinical features. Int J Cancer 1999;83:815-22.
4. Skotheim RI, Monni O, Mousses S, et al. New insights into testicular germ cell tumorigenesis from gene expression profiling. Cancer Res 2002;62:2359-64.
5. Atkin NB, Baker MC. i(12p): specific chromosomal marker in seminoma and malignant teratoma of the testis? Cancer Genet Cytogenet 1983;10:199-204.
6. Frigyesi A, Gisselsson D, Hansen GB, Soller M, Mitelman F, Hoglund M. A model for karyotypic evolution in testicular germ cell tumors. Genes Chromosomes Cancer 2004;40:172-8.
7. Laguna MP, Pizzocaro G, Klepp O, Algaba F, Kisbenedek L, Leiva O. EAU guidelines on testicular cancer. Eur Urol 2001;40:102-10.
8. Peckham MJ, Hamilton CR, Norwich A, Hendry WF. Surveillance after orchiectomy for stage I seminoma of thetestis. Br J Urol 1987;59:343-7.
9. Maier JG, Sulak MH, Mittemeyer BT. Seminoma of the testis: analysis of treatment success and failure. Am J Roentgenol Radium Ther Nucl Med 1968;102:596-602.
10. Warde P, Specht L, Norwich A, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002;20:4448-52.
11. Warde P, Gospodarowicz MK, Banerjee D, et al. Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. J Urol 1997;157:1705-9, Discussion 1709-10.
12. Warde PR, Gospodarowicz MK, Goodman PJ, et al. Results of a policy of surveillance in stage I testicular seminoma. Int J Radiat Oncol Biol Phys 1993;27:11-5.
13. von der Maase H, Specht L, Jacobsen GK, et al. Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer 1993;29A:1931-4.
14. Norwich A, Alsanjari N, A'Hern R, Nicholls J, Dearnaley DP, Fisher C. Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer 1992;65:775-8.
15. Travis LB. Therapy-associated solid tumors. Acta Oncol 2002;41:323-33.
16. Travis LB, Andersson M, Gospodarowicz M, et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 2000;92:1165-71.
17. Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429-39.
18. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
19. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;98:5116-21.
20. Cheville JC, Rao S, Iczkowski KA, Lohse CM, Pankratz VS. Cytokeratin expression in seminoma of the human testis. Am J Clin Pathol 2000;113:583-8.
21. Kemmer K, Corless CL, Fletcher JA, et al. KIT mutations are common in testicular seminomas. Am J Pathol 2004;164:305-13.
22. Madani A, Kemmer K, Sweeney C, et al. Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. Ann Oncol 2003;14:873-80.
23. Okada K, Katagiri T, Tsunoda T, et al. Analysis of gene-expression profiles in testicular seminomas using a genome-wide cDNA microarray. Int J Oncol 2003;23:1615-35.
24. Skotheim RI, Abeler VM, Nesland JM, et al. Candidate genes for testicular cancer evaluated by in situ protein expression analyses on tissue microarrays. Neoplasia 2003;5:397-404.
25. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000;18:498-509.
26. Bokemeyer C, Schmoll HJ. Treatment of testicular cancer and the development of secondary malignancies. J Clin Oncol 1995;13:283-92.